Covered recipient · General Payments record
NARENDRA SINGH
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$176,862.72
180 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $147,884.00 | 60 |
| Travel and Lodging | $13,366.16 | 36 |
| Consulting Fee | $7,715.00 | 6 |
| Honoraria | $4,050.00 | 2 |
| Food and Beverage | $3,766.56 | 74 |
| Education | $81.00 | 2 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Pharmaceuticals, Inc | $59,968.68 | 45 |
| AstraZeneca Pharmaceuticals LP | $47,754.50 | 49 |
| Esperion Therapeutics, Inc. | $23,813.79 | 19 |
| Lilly USA, LLC | $14,605.86 | 8 |
| Amgen Inc. | $11,004.99 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $8,013.47 | 15 |
| PORTOLA PHARMACEUTICALS, LLC | $5,646.22 | 6 |
| Eli Lilly and Company | $5,400.00 | 2 |
| Bardy Diagnostics, Inc. | $167.00 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $125.00 | 1 |
| Amarin Pharma Inc. | $89.30 | 4 |
| Astellas Pharma US Inc | $86.16 | 2 |
| Edwards Lifesciences Corporation | $49.43 | 2 |
| SANOFI-AVENTIS U.S. LLC | $29.88 | 2 |
| Novo Nordisk Inc | $28.86 | 2 |
| Actelion Pharmaceuticals US, Inc. | $28.17 | 1 |
| Regeneron Healthcare Solutions, Inc. | $24.45 | 2 |
| Abbott Laboratories | $19.19 | 1 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $7.77 | 1 |
Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NARENDRA SINGH
NPI 1760477202 · CMS profile ID 352791
Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
JOHNS CREEK, GA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1760477202?year=2020&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NARENDRA SINGH, NPI 1760477202, CMS profile ID 352791. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1760477202?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). NARENDRA SINGH, NPI 1760477202, CMS profile ID 352791. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1760477202?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- NARENDRA SINGH, NPI 1760477202, CMS profile ID 352791, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 180 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1760477202?year=2020&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
180 matching records · $176,862.72 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 180.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $250.00 | 05/27/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736122003 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $15.04 | 05/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720587335 | CMS |
| PORTOLA PHARMACEUTICALS, LLC | $21.76 | 04/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725051957 | CMS |
| PORTOLA PHARMACEUTICALS, LLC | $800.00 | 04/28/2020 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725051973 | CMS |
| Lilly USA, LLC | $15.26 | 04/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728576193 | CMS |
| Lilly USA, LLC | $35.23 | 04/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728599965 | CMS |
| Lilly USA, LLC | $155.37 | 04/23/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728599967 | CMS |
| Janssen Pharmaceuticals, Inc | $26.48 | 04/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327593 | CMS |
| Janssen Pharmaceuticals, Inc | $300.00 | 04/16/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327591 | CMS |
| Janssen Pharmaceuticals, Inc | $1,430.00 | 04/02/2020 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327589 | CMS |
| Amgen Inc. | $2,100.00 | 03/25/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741244125 | CMS |
| Amgen Inc. | $17.51 | 03/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741244117 | CMS |
| Lilly USA, LLC | $6,900.00 | 03/23/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728586327 | CMS |
| Janssen Pharmaceuticals, Inc | $4,600.00 | 03/20/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327583 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,700.00 | 03/16/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736344739 | CMS |
| AstraZeneca Pharmaceuticals LP | $20.26 | 03/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736054781 | CMS |
| Janssen Pharmaceuticals, Inc | $4,600.00 | 03/11/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327581 | CMS |
| Lilly USA, LLC | $600.00 | 03/11/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728576191 | CMS |
| Janssen Pharmaceuticals, Inc | $125.00 | 03/10/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327577 | CMS |
| Janssen Pharmaceuticals, Inc | $1,012.12 | 03/10/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327579 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $60.89 | 03/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720587311 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $51.42 | 03/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720587315 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $145.00 | 03/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720587321 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $346.76 | 03/07/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720587339 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $27.06 | 03/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720587345 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $49.48 | 03/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720587349 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $380.11 | 03/07/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 720587357 | CMS |
| Janssen Pharmaceuticals, Inc | $4,000.00 | 03/06/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327561 | CMS |
| Janssen Pharmaceuticals, Inc | $4,000.00 | 03/06/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327563 | CMS |
| Janssen Pharmaceuticals, Inc | $34.50 | 03/06/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327565 | CMS |
| Astellas Pharma US Inc | $69.99 | 03/05/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 718383919 | CMS |
| Janssen Pharmaceuticals, Inc | $86.55 | 03/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327573 | CMS |
| Janssen Pharmaceuticals, Inc | $619.28 | 03/04/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327575 | CMS |
| Amgen Inc. | $23.58 | 03/03/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741244121 | CMS |
| Amgen Inc. | $2,800.00 | 03/03/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741244127 | CMS |
| Janssen Pharmaceuticals, Inc | $4,000.00 | 02/28/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327557 | CMS |
| Janssen Pharmaceuticals, Inc | $33.35 | 02/28/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327559 | CMS |
| Amgen Inc. | $109.39 | 02/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741244129 | CMS |
| Actelion Pharmaceuticals US, Inc. | $28.17 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327519 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,700.00 | 02/26/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 736142453 | CMS |
| Janssen Pharmaceuticals, Inc | $4,000.00 | 02/26/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327553 | CMS |
| Janssen Pharmaceuticals, Inc | $20.70 | 02/26/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327555 | CMS |
| Janssen Pharmaceuticals, Inc | $92.93 | 02/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327571 | CMS |
| Janssen Pharmaceuticals, Inc | $100.00 | 02/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327533 | CMS |
| Janssen Pharmaceuticals, Inc | $717.49 | 02/25/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327535 | CMS |
| Amgen Inc. | $14.95 | 02/24/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741244119 | CMS |
| Amgen Inc. | $2,800.00 | 02/24/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741244123 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.04 | 02/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735781191 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.65 | 02/24/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 735816363 | CMS |
| Janssen Pharmaceuticals, Inc | $104.17 | 02/24/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719327537 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $913,209.94 | 320 |
| PY2024 | Principal investigator | $859,158.68 | 68 |
| PY2023 | Principal investigator | $685,181.93 | 69 |
| PY2022 | Principal investigator | $282,066.10 | 114 |
| PY2021 | Recipient | $443.08 | 1 |
| PY2021 | Principal investigator | $346,566.50 | 140 |
| PY2020 | Recipient | $1,302.46 | 1 |
| PY2020 | Principal investigator | $266,041.62 | 226 |
| PY2019 | Principal investigator | $482,164.44 | 117 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
320 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $9,108.34 | 12/31/2025 | Non-covered Recipient Entity NSC Research | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction | No dispute reported | 06/30/2026 | 1232920764 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 12/17/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676955 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 12/17/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 12/15/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676743 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 12/15/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676745 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 12/15/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676747 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 12/15/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676749 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 12/15/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676751 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 12/15/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676753 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 12/15/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676755 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 12/15/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676757 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,276.00 | 12/15/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676759 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $179.00 | 12/15/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676761 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,097.00 | 12/15/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676763 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 12/15/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676765 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,327.50 | 12/15/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809901 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,034.00 | 12/12/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209394 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $6,000.00 | 12/09/2025 | Non-covered Recipient Entity NSC Cardiology - Johns Creek | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508320 |
| Principal investigator 1 | Alnylam Pharmaceuticals Inc. | $2,598.00 | 12/09/2025 | Non-covered Recipient Entity NSC Cardiology - Johns Creek | A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease | No dispute reported | 06/30/2026 | 1215508323 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676739 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676741 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676935 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676939 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676941 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676945 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220676987 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,224.00 | 11/26/2025 | Non-covered Recipient Entity NSC RESEARCH | a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure | No dispute reported | 06/30/2026 | 1185553443 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 11/21/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676733 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,276.00 | 11/21/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676735 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 11/21/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676737 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,236.00 | 11/19/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209313 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,338.48 | 11/14/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220996202 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,563.10 | 11/13/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809899 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,347.00 | 11/07/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209371 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,057.00 | 11/05/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209413 |
| Principal investigator 1 | Janssen Research & Development, LLC | $969.00 | 11/03/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209304 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676729 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676731 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676923 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676929 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676933 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220676985 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $10,015.45 | 10/30/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220996218 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 10/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676947 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,350.50 | 10/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676949 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $50.46 | 10/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676951 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.04 | 10/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676953 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 10/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220676969 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,730.00 | 10/27/2025 | Non-covered Recipient Entity NSC RESEARCH INC | A Non-Interventional Survey Study on the Preferences of Patients with Atrial Fibrillation and Physicians Treating Atrial Fibrillation for Anticoagulant Treatment Outcomes | No dispute reported | 06/30/2026 | 1175420642 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 10/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676705 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 10/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676707 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 10/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676709 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 10/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676711 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147.00 | 10/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676713 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,423.00 | 10/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676715 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,276.00 | 10/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676717 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 10/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676719 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 10/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676721 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,423.00 | 10/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676723 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,204.00 | 10/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676725 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $97.00 | 10/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676727 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 10/17/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220996204 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 10/08/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676695 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $728.00 | 10/08/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676697 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $540.00 | 10/08/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676699 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,150.00 | 10/08/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676701 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $714.00 | 10/08/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676703 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 10/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676691 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 10/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676693 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676911 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676915 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676917 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220676983 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,669.24 | 09/26/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220996198 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,338.48 | 09/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220996216 |
| Principal investigator 1 | Amgen Inc. | $3,457.17 | 09/24/2025 | Non-covered Recipient Entity NSC RESEARCH INC. | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246645714 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 09/24/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676681 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 09/24/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676683 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.00 | 09/24/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676685 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.44 | 09/24/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676687 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11.28 | 09/24/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676689 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 09/24/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 09/24/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220676967 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,210.00 | 09/23/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809897 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 09/22/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798229 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,773.00 | 09/19/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209342 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,693.90 | 09/18/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809895 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,338.48 | 09/12/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220996200 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $8,684.60 | 09/08/2025 | Non-covered Recipient Entity NSC Research | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction | No dispute reported | 06/30/2026 | 1232920762 |
| Principal investigator 1 | Organon Llc | $2,500.00 | 09/08/2025 | Non-covered Recipient Entity NSC Research Inc | 1242-035 | No dispute reported | 06/30/2026 | 1173042422 |
| Principal investigator 1 | Organon Llc | $1,000.00 | 09/08/2025 | Non-covered Recipient Entity NSC Research Inc | 1242-035 | No dispute reported | 06/30/2026 | 1173042424 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 09/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676629 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 09/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676631 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 09/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676867 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676885 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676887 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220676981 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,023.00 | 08/25/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209381 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $11,684.68 | 08/21/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220996214 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 08/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676637 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,423.00 | 08/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676639 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,423.00 | 08/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676641 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,720.00 | 08/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676643 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 08/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676673 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,758.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676645 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676647 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676649 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,380.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676651 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,720.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676653 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,380.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676655 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,720.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676657 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,380.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676659 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,720.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676661 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,380.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676663 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,758.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676665 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,758.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676667 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,758.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676669 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 08/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676671 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $13,947.30 | 08/06/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 08/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676625 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 08/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676627 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676869 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676871 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676873 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676875 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220676979 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $239.76 | 07/28/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676675 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 07/28/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676677 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.76 | 07/28/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676679 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 07/28/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 07/28/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 07/28/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220676965 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,828.00 | 07/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676611 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,310.00 | 07/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676613 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,097.00 | 07/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676615 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,660.00 | 07/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676617 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,204.00 | 07/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676619 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $266.00 | 07/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676621 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $206.00 | 07/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676623 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,669.24 | 07/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220996196 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,955.00 | 07/23/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209365 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $10,511.10 | 07/19/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809891 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 07/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676633 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 07/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676635 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676891 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676895 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676897 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676899 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 07/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220676971 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 07/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220676973 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 07/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220676975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220676977 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 06/24/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676605 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 06/24/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676607 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 06/24/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676609 |
| Principal investigator 1 | Janssen Research & Development, LLC | $216.00 | 06/23/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209321 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $266.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676561 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,660.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676563 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $266.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676565 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,310.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676567 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,660.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676569 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,828.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676571 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $179.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676573 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,097.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676575 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $266.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676577 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $266.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676579 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $266.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676581 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $266.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676583 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $266.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676585 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,955.00 | 06/20/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209334 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $266.00 | 06/04/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676541 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,310.00 | 06/04/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676543 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $147.00 | 06/04/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676545 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,828.00 | 06/04/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676547 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,828.00 | 06/04/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676549 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,204.00 | 06/04/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676551 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,828.00 | 06/04/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676553 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,204.00 | 06/04/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676555 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,097.00 | 06/04/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676557 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,310.00 | 06/04/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676559 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 06/04/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220996194 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 06/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676537 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 06/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676539 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676843 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.88 | 06/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676845 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 06/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676847 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 06/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676849 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676851 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676853 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676855 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676857 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676859 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $179.82 | 05/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676597 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 05/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676599 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.35 | 05/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676601 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.58 | 05/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676603 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 05/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676865 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $34.98 | 05/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220676959 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $359.64 | 05/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220676961 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 05/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% | No dispute reported | 06/30/2026 | 1220676963 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,361.00 | 05/21/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209295 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,669.24 | 05/15/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220996208 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $1,669.24 | 05/13/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220996210 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,400.90 | 05/09/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 05/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676533 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 05/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676535 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676831 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676833 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676835 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676837 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676839 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676841 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,206.00 | 05/01/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809885 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $1,122.00 | 05/01/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809887 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $206.00 | 04/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676525 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,204.00 | 04/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676527 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $206.00 | 04/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,660.00 | 04/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676531 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $459.54 | 04/23/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676587 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 04/23/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676589 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 04/23/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676591 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.10 | 04/23/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676593 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.88 | 04/23/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676595 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 04/23/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676861 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 04/23/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676863 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,683.00 | 04/23/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209403 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $10,015.45 | 04/22/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220996212 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,067.50 | 04/11/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809883 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $108.00 | 04/09/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798225 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8.00 | 04/09/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798227 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $91.00 | 04/07/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676517 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $225.00 | 04/07/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676519 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,744.00 | 04/07/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676521 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $692.00 | 04/07/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676523 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 04/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676513 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 04/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676515 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676817 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676819 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676821 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676823 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676825 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 04/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676827 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676829 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,317.40 | 03/24/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809881 |
| Principal investigator 1 | Janssen Research & Development, LLC | $9,541.00 | 03/21/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209358 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,204.00 | 03/19/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676493 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,204.00 | 03/19/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676495 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,828.00 | 03/19/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676497 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $206.00 | 03/19/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676499 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,310.00 | 03/19/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676501 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,007.72 | 03/14/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220996206 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $129.00 | 03/14/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220798223 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 03/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676487 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 03/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676489 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676789 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676791 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676793 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676795 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676797 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676799 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $206.00 | 02/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676481 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 02/25/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676511 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,520.00 | 02/19/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209389 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $162,423.20 | 02/17/2025 | Non-covered Recipient Entity ATLANTA HEART SPECIALISTS CUMMING | HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190313263 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $742.50 | 02/13/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 02/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676483 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 02/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676485 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676777 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676779 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676781 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676785 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.00 | 01/31/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676491 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 01/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 01/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676505 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.61 | 01/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676507 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.70 | 01/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 01/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676801 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.00 | 01/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676803 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $221.10 | 01/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676805 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.86 | 01/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676807 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 01/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676809 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.44 | 01/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676811 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.28 | 01/27/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676813 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,870.60 | 01/27/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809877 |
| Principal investigator 1 | Eli Lilly and Company | $781.62 | 01/27/2025 | Non-covered Recipient Entity NSC RESEARCH INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187887360 |
| Principal investigator 1 | Eli Lilly and Company | $1,054.52 | 01/27/2025 | Non-covered Recipient Entity NSC RESEARCH INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187888838 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,179.00 | 01/22/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676472 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $206.00 | 01/22/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676474 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,301.00 | 01/22/2025 | Non-covered Recipient Entity Nsc Rsrch | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175209350 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,346.20 | 01/17/2025 | Non-covered Recipient Entity NSC Research Inc | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220809875 |
| Principal investigator 1 | Eli Lilly and Company | $38,784.00 | 01/07/2025 | Non-covered Recipient Entity NSC RESEARCH INC | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | No dispute reported | 06/30/2026 | 1187888032 |
| Principal investigator 1 | Eli Lilly and Company | $151,253.00 | 01/07/2025 | Non-covered Recipient Entity NSC RESEARCH INC | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187888446 |
| Principal investigator 1 | Amgen Inc. | $91,725.98 | 01/06/2025 | Non-covered Recipient Entity NSC RESEARCH INC. | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke | No dispute reported | 06/30/2026 | 1246645722 |
| Principal investigator 1 | Amgen Inc. | $21,714.29 | 01/03/2025 | Non-covered Recipient Entity NSC RESEARCH INC. | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246645718 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676476 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220676479 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676767 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676769 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676771 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676773 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676775 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Nsc Cardiology-Johns Creek | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220676815 |